Overview

Bone Metastasis on the Survival of Gefitinib Effective Patients

Status:
Completed
Trial end date:
2015-07-12
Target enrollment:
0
Participant gender:
All
Summary
Gefitinib is a selective small molecule epidermal growth factor receptors (EGFR) tyrosine kinase inhibitors (EGFR-TKI), it's curative effect on non-small cell lung cancer (NSCLC) has been confirmed by a number of prospective clinical trials. The researches aim to analysis whether bone metastasis could affect the survival of NSCLC patients who were effective in Gefitinib treatment over 6 months.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Qilu Hospital of Shandong University
Treatments:
Gefitinib
Criteria
Inclusion Criteria:

1. histological and (or) cytological diagnosed NSCLC patients.

2. patient was effective in Gefitinib treatment more than 6 months.

3. whether patient received chemotherapy and other treatment is not restricted.

4. whether patient was detected for EGFR gene mutation was not restricted.

Exclusion Criteria:

1. patient with small cell lung cancer.

2. patient without cytology or histopathology diagnosis results.

3. patient with bone metastases cannot rule out other reasons such as inflammation or
trauma.

4. patient with poor treatment compliance.

5. patient with incomplete data.